2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia
artículo científico publicado en 2003
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
artículo científico publicado en 2013
A Phase 1-11 Study of High-Dose Thiotepa, Busulfan and Cyclophosphamide as a Preparative Regimen for Autologous Transplantation for Malignant Lymphoma
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer
artículo científico publicado en 2011
A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thal
scientific article published on 05 November 2019
A new pet for myeloma
article
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis
article by Efstathios Kastritis et al published 18 April 2012 in Blood
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.
artículo científico publicado en 2015
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
artículo científico publicado en 2002
A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial.
artículo científico publicado en 2018
A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
artículo científico publicado en 2002
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.
artículo científico publicado en 2004
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
artículo científico publicado en 2013
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.
artículo científico publicado en 2010
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study
artículo científico publicado en 2008
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
artículo científico publicado en 2010
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
artículo científico publicado en 2016
A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study
artículo científico publicado en 2011
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide
artículo científico publicado en 2012
A review of the impact of weather and climate variables to COVID-19: In the absence of public health measures high temperatures cannot probably mitigate outbreaks
artículo científico publicado en 2020
A review of the venous thrombotic issues associated with multiple myeloma
artículo científico publicado en 2016
A revised international prognostic score system for Waldenström's macroglobulinemia
artículo científico publicado en 2019
A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
artículo científico publicado en 2011
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
scientific article published on 19 August 2019
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation
artículo científico publicado en 2016
A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma
artículo científico publicado en 2012
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer
artículo científico publicado en 2015
Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton
scientific article published on 01 January 2007
Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia
artículo científico publicado en 2006
Acute lobar nephronia as the presenting manifestation of hyperparathyroidism.
artículo científico publicado en 1997
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
artículo científico publicado en 2017
Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma.
artículo científico publicado en 2011
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2004
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2004
Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience
artículo científico publicado en 2006
Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
artículo científico publicado en 2005
Advances in imaging and the management of myeloma bone disease
scientific article published on 11 April 2011
Advances in the treatment of multiple myeloma
article
Adverse effects of thalidomide administration in patients with neoplastic diseases
artículo científico publicado en 2004
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.
artículo científico publicado en 2017
Age-related thymic activity in adults following chemotherapy-induced lymphopenia
Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies
artículo científico publicado en 2018
Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies
Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation
artículo científico publicado el 1 de septiembre de 1992
Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation
scientific article published on 01 June 1994
Ambulatory blood pressure monitoring in acute stroke
artículo científico publicado en 2012
Ambulatory blood pressure monitoring in acute stroke: pathophysiology of the time rate of blood pressure variation and association with the 1-year outcome
artículo científico publicado en 2013
Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis.
artículo científico
An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when
scholarly article by Jo Caers et al published 31 August 2018 in Haematologica
An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone
article
An overview of the role of carfilzomib in the treatment of multiple myeloma
artículo científico publicado en 2017
An update on the use of lenalidomide for the treatment of multiple myeloma
artículo científico
Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
article
Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma
artículo científico publicado en 2016
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
artículo científico publicado en 2017
Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
artículo científico publicado en 2018
Angiogenesis in human cancer: implications in cancer therapy.
artículo científico publicado en 2003
Angiogenesis-related pathways in the pathogenesis of ovarian cancer
artículo científico publicado en 2013
Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma
artículo científico publicado en 2013
Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
artículo científico publicado en 2020
Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies
Antimyosin Scintigraphy for Detection of Cardiac Amyloidosis
article
Applications of monoclonal antibodies for the treatment of hematological malignancies
artículo científico publicado en 2009
Appraising myc involvement in high risk myeloma
Aromatase inhibitors in male breast cancer: a pooled analysis
artículo científico publicado en 2015
Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts.
artículo científico publicado en 2009
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study
artículo científico publicado en 2012
Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer
artículo científico publicado en 2014
Asymptomatic Waldenstrom's macroglobulinemia.
artículo científico publicado en 2003
Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with -catenin levels and outcome in patients with epithelial ovarian cancer
article
Avascular Osteonecrosis of the Jaw as a Side Effect of Bisphosphonate Treatment
article
BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
artículo científico publicado en 2016
Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis?
scientific article published on 01 June 2005
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
artículo científico publicado en 2010
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
artículo científico publicado en 2017
Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment
artículo científico publicado en 2007
Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer
artículo científico publicado en 2008
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma
Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group
artículo científico publicado en 2021
Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases.
artículo científico publicado en 1999
Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group
scientific article published on 06 March 2019
Bortezomib as a treatment option in patients with Waldenström macroglobulinemia
artículo científico publicado en 2010
Bortezomib for AL amyloidosis: moving forward
Bortezomib in multiple myeloma
artículo científico publicado en 2008
Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial
artículo científico publicado en 2010
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
artículo científico publicado en 2008
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
artículo científico publicado en 2006
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis
artículo científico publicado en 2010
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
artículo científico publicado en 2016
Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential Hypertension.
artículo científico publicado en 2017
Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy
artículo científico publicado en 2006
Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature
artículo científico publicado en 2005
Breast Cancer in Women Aged 25 Years and Younger
scientific article published on 01 June 2013
Breast cancer and second primary ovarian cancer in dermatomyositis
artículo científico publicado en 1991
Burkitt's lymphoma in Greek adults. A study of the Hellenic co-operative oncology group
Burkitt’s Lymphoma in Pregnancy with Bilateral Breast Involvement: Case Report with Review of the Literature
⬇️
artículo científico publicado el 26 de julio de 2010
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2007
COVID-19: time to flatten the infodemic curve
artículo científico publicado en 2021
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma
artículo científico publicado en 2011
Cadmium content in foodstuffs from the Greek market
artículo científico publicado en 2002
Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study
Carboplatin hypersensitivity reactions: a single institution experience
artículo científico publicado en 2005
Carcinosarcoma of the Bladder
artículo científico publicado en 1991
Cardiac and renal complications of carfilzomib in patients with multiple myeloma
artículo científico publicado en 2017
Carfilozomib versus bortezomib for relapsed or refractory myeloma – Authors' reply
scientific article published on 29 March 2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
artículo científico publicado en 2015
Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
artículo científico publicado en 2017
Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors
artículo científico publicado en 2015
Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply
artículo científico publicado en 2018
Carfilzomib for treating myeloma
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
artículo científico publicado en 2017
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
scientific article published on 28 February 2019
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
artículo científico publicado en 2016
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
scholarly article by Athanasios Dimopoulos et al published 10 January 2019 in Blood
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
article
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
artículo científico publicado en 2017
Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
artículo científico publicado en 2019
Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients
scientific article published on 03 November 2020
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
artículo científico publicado en 2017
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.
artículo científico publicado en 2016
Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations
scientific article published on 03 April 2020
Challenges in managing breast cancer during pregnancy.
artículo científico publicado en 2013
Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity
artículo científico publicado en 2020
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating
artículo científico publicado en 2011
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
scientific article published on 22 August 2019
Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma
artículo científico publicado en 2014
Circulating Levels of Angiogenic Cytokines in Waldenstrom’s Macroglobulinemia: Clinical Correlations
Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia
artículo científico publicado en 2018
Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction
artículo científico publicado en 2020
Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.
artículo científico publicado en 2012
Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.
artículo científico publicado en 2011
Cisplatin, Ifosfamide, Methotrexate and Vinblastine Combination Chemotherapy for Metastatic Urothelial Cancer
⬇️
artículo científico publicado el 1 de agosto de 1997
Clinical Perspectives of ERCC1 in Bladder Cancer
scientific article published on 22 November 2020
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens
artículo científico publicado en 2013
Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis
artículo científico publicado en 2016
Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece.
artículo científico publicado en 2010
Clinical characteristics of patients with relapsed multiple myeloma
artículo científico publicado en 2015
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.
artículo científico publicado en 2012
Clinical experience with fludarabine in hemato-oncology.
artículo científico publicado en 1996
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
scientific article published on 14 April 2020
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients.
artículo científico publicado en 2014
Clinical implications of chromosomal abnormalities in multiple myeloma.
artículo científico publicado en 2006
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
artículo científico publicado en 2003
Clinicopathological features of ovarian carcinosarcomas: a single institution experience
artículo científico publicado en 2005
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases
Collecting duct carcinoma of the kidney
artículo científico publicado en 1993
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group
artículo científico publicado en 2007
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2001
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2005
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group
artículo científico publicado en 2000
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study
artículo científico publicado en 2004
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment
artículo científico publicado en 2005
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2002
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma
scientific article published on 15 May 2010
Common breast cancer susceptibility loci are associated with triple-negative breast cancer
artículo científico publicado en 2011
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.
artículo científico publicado en 2014
Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomize
artículo científico publicado en 2001
Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy
artículo científico publicado en 2015
Complete Testicular Feminisation Syndrome in Three Sisters
artículo científico publicado en 1990
Complications and supportive therapy of multiple myeloma
artículo científico publicado en 1995
Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)
artículo científico publicado en 2015
Consensus on the utility of bone markers in the malignant bone disease setting
artículo científico publicado en 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
artículo científico publicado en 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
artículo científico publicado en 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
artículo científico publicado en 2011
Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients
artículo científico publicado en 2014
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates
artículo científico publicado en 2019
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with mu
artículo científico publicado en 2020
Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies.
artículo científico publicado en 2017
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma
article
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
artículo científico publicado en 2015
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherap
article by Aristotelis Bamias et al published February 2008 in Gynecologic Oncology
Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients
artículo científico publicado en 2001
Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States
scientific article published on 06 April 2020
Could rigorous diagnosis and management of hypertension reduce cardiac events in patients with renal cell carcinoma treated with tyrosine kinase inhibitors?
artículo científico publicado en 2009
Curability of solitary bone plasmacytoma
artículo científico publicado en 1992
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation
artículo científico
Current Treatment of Relapsed Ovarian Carcinoma
Current multiple myeloma treatment strategies with novel agents: a European perspective
scientific article published on 19 January 2010
Current therapy guidelines for Waldenstrom's macroglobulinaemia
artículo científico publicado en 2016
Current treatment landscape for relapsed and/or refractory multiple myeloma
artículo científico publicado en 2014
Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia
artículo científico publicado en 2017
Current treatments for renal failure due to multiple myeloma
artículo científico
Current treatments for renal failure due to multiple myeloma
artículo científico publicado en 2016
Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma.
artículo científico publicado en 1993
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
artículo científico publicado en 2009
Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects
artículo científico publicado en 2016
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
artículo científico publicado en 2015
DIAGNOSIS, RISK-STRATIFICATION, AND MANAGEMENT OF SOLITARY PLASMACYTOMA
DNA damage, tumor mutational load and their impact on immune responses against cancer
artículo científico publicado en 2016
DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.
artículo científico publicado en 2016
Daratumumab combinations: what can we learn?
artículo científico publicado en 2017
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
artículo científico publicado en 2016
Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.
artículo científico publicado en 2018
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
scientific article published on 03 November 2020
Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance
scientific article published on 23 August 2020
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma
scientific article published on 04 November 2020
Defining Waldenstrom's macroglobulinemia
artículo científico publicado en 2003
Denosumab for myeloma bone disease: ready for prime time?
artículo científico publicado en 2018
Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies
artículo científico publicado en 2018
Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging.
artículo científico publicado en 2003
Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.
artículo científico publicado en 2012
Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
artículo científico publicado en 2013
Developments in the systemic treatment of endometrial cancer.
artículo científico publicado en 2010
Developments in the systemic treatment of metastatic cervical cancer.
artículo científico
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study
article
Diagnosis and management of Waldenstrom's macroglobulinemia
artículo científico publicado en 2005
Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib.
artículo científico publicado en 2009
Diagnostic work-up and specific causes of acute kidney injury
artículo científico publicado en 2017
Dickkopf-1: a suitable target for the management of myeloma bone disease.
scientific article published on July 2009
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel
artículo científico publicado en 2012
Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients
artículo científico publicado en 2012
Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.
artículo científico publicado en 2004
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal
artículo científico
Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece.
artículo científico publicado en 2014
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results
artículo científico publicado el 1 de agosto de 1997
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 1999
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group
artículo científico publicado en 2003
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2003
Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy?
artículo científico publicado en 1996
Does pregnancy-associated breast cancer imply a worse prognosis? A matched case-case study.
artículo científico publicado en 2013
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
artículo científico publicado en 2001
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer.
artículo científico publicado en 2001
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2001
Dosing of thioTEPA for myeloablative therapy
scientific article published on 01 January 1995
Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma.
artículo científico publicado en 2017
Early myeloablative therapy for multiple myeloma.
artículo científico publicado en 1994
Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma
artículo científico publicado en 2015
Editorial Comment on: New treatment approaches for prostate cancer based on peptide analogues
Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer
artículo científico publicado en 2005
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
artículo científico publicado en 2015
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma
scientific article published on 22 January 2019
Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
article
Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress.
artículo científico publicado en 2010
Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study
artículo científico publicado en 2009
Efficacy and safety of elotuzumab for the treatment of multiple myeloma
artículo científico publicado en 2017
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
artículo científico publicado en 2014
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies
artículo científico publicado en 2020
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
article
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis
artículo científico publicado en 2018
Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis
artículo científico publicado en 2010
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
artículo científico publicado en 2011
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
artículo científico publicado en 2015
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
scientific article published on 04 November 2019
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
artículo científico publicado en 2018
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth
artículo científico publicado en 2017
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
artículo científico publicado en 2020
Emerging antibodies for the treatment of multiple myeloma
artículo científico publicado en 2016
Emerging drugs for Waldenström's macroglobulinemia
⬇️
artículo científico publicado el 1 de marzo de 2011
Emerging drugs for the treatment of Waldenström macroglobulinemia
scientific article published on 21 September 2020
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
artículo científico publicado en 2010
Emerging treatment approaches for myeloma-related bone disease
artículo científico publicado en 2017
Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: A case report and review of the literature
article
Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
artículo científico publicado en 2009
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience
artículo científico publicado en 2007
Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.
artículo científico publicado en 2015
Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
artículo científico publicado en 2016
Erratum: International uniform response criteria for multiple myeloma
scholarly article published in Leukemia
Erratum: International uniform response criteria for multiple myeloma
article
Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
scholarly article published in Leukemia
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease
artículo científico publicado en 2011
European Myeloma Network guidelines for the management of multiple myeloma-related complications
artículo científico publicado en 2015
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
artículo científico publicado en 2014
European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses.
artículo científico publicado en 2012
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias
artículo científico publicado en 2018
European perspective on multiple myeloma treatment strategies in 2014
artículo científico publicado en 2014
European perspective on multiple myeloma treatment strategies: update following recent congresses
artículo científico publicado en 2012
Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.
artículo científico publicado en 2018
Evaluation of the Prognostic Value of Cellular Inhibitor of Apoptosis Protein in Epithelial Ovarian Cancer Using Automated Quantitative Protein Analysis
artículo científico publicado en 2006
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
artículo científico publicado en 2016
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
artículo científico publicado en 2008
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co
artículo científico publicado en 2013
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy
artículo científico publicado en 2006
Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced Inflammation
artículo científico publicado en 2016
Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective
artículo científico
Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma
scientific article published on 01 February 2003
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
artículo científico publicado en 2014
Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients
artículo científico publicado en 2016
Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.
artículo científico publicado en 2009
Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?
artículo científico publicado en 2015
Expression of CCL3 by Neoplastic Cells in Patients with Waldenström's Macroglobulinemia: An Immunohistochemical Study in Bone Marrow Biopsies of 67 Patients
artículo científico publicado en 2011
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study
artículo científico publicado en 2011
Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in localized prostate cancer
artículo científico publicado en 2015
Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia
artículo científico publicado en 2002
Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease
artículo científico publicado en 2012
Extent of Damage and Repair in thep53Tumor-Suppressor Gene After Treatment of Myeloma Patients With High-Dose Melphalan and Autologous Blood Stem-Cell Transplantation Is Individualized and May Predict Clinical Outcome
article
Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature
artículo científico publicado en 2006
Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
artículo científico publicado en 2013
Familial female and male germ cell cancer. A new syndrome?
Favorable Outcome of Ovarian Germ Cell Malignancies Treated with Cisplatin or Carboplatin-Based Chemotherapy: A Hellenic Cooperative Oncology Group Study
Female breast cancer in Europe: statistics, diagnosis and treatment modalities
⬇️
artículo científico publicado en 2014
Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
article
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
artículo científico publicado en 2017
First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study
artículo científico publicado en 2001
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study
artículo científico publicado en 1998
Fludarabine therapy in Waldenström's macroglobulinemia
scientific article published on 01 July 1993
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
artículo científico publicado en 2006
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives
artículo científico publicado en 2018
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial
artículo científico publicado en 1999
Fulvestrant and male breast cancer: a pooled analysis.
artículo científico publicado en 2014
G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting
artículo científico publicado en 2001
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group
artículo científico publicado en 2004
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2000
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
artículo científico publicado en 2005
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy
artículo científico publicado en 2017
Genetic predisposition for the development of ONJ
article
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
artículo científico publicado en 2013
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report
artículo científico publicado en 2015
Gestational trophoblastic neoplasia with retroperitoneal metastases: a fatal complication.
artículo científico publicado en 2010
Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis
artículo científico publicado en 2015
Glomerular expression of matrix metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy
artículo científico publicado en 2015
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis
artículo científico publicado en 2018
Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome
artículo científico publicado en 2016
Gynecologic oncology patients in the surgical high dependency unit: an analysis of indications
artículo científico publicado en 2014
Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
artículo científico publicado en 2016
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
artículo científico publicado en 2014
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
article
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
scientific article published on 09 April 2020
Hematologic Response and Stabilization of Renal Function in a Patient With Light Chain Deposition Disease After Lenalidomide Treatment: A Novel Therapeutic Approach?
article
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.
artículo científico publicado en 2016
Hematological findings and complications of COVID-19
artículo científico publicado en 2020
Hematological malignancies: myeloma
artículo científico publicado en 2006
Hematology: first-line bortezomib benefits patients with multiple myeloma
artículo científico publicado en 2009
High Dose Therapy with Autologous Stem Cell Transplantation for Solitary Bone Plasmacytoma Complicated by Local Relapse or Isolated Distant Recurrence
High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
artículo científico publicado en 2013
High dose melphalan in primary systemic amyloidosis: status quo?
⬇️
artículo científico publicado el 1 de diciembre de 2010
High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
artículo científico publicado en 2008
High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma
artículo científico publicado en 2016
High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents
artículo científico publicado en 2009
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents
artículo científico publicado en 2010
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma
artículo científico publicado en 1991
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma
scholarly article by Anjan Thakurta et al published 14 March 2019 in Blood
High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia
artículo científico publicado en 2001
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity
artículo científico publicado el 1 de abril de 1995
High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial
artículo científico publicado en 2007
Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria.
artículo científico publicado en 1999
Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study
artículo científico publicado en 2004
How lenalidomide is changing the treatment of patients with multiple myeloma
artículo científico
How to manage neutropenia in multiple myeloma
artículo científico
How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide
artículo científico publicado en 2007
How we treat Waldenström's macroglobulinemia
artículo científico publicado en 2005
Hsp90 inhibitors in breast cancer: a systematic review.
artículo científico publicado en 2013
Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression
artículo científico publicado en 2008
HyperCVAD for VAD-resistant multiple myeloma
scientific article published on 01 June 1996
Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia
artículo científico publicado en 2011
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
artículo científico publicado en 2016
Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer
artículo científico publicado en 1997
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer
artículo científico publicado en 2000
Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer
artículo científico publicado en 2001
Imaging of myeloma bone disease--implications for staging, prognosis and follow-up
artículo científico publicado en 2000
Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization
artículo científico publicado en 2010
Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents
artículo científico publicado en 2014
Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas
artículo científico publicado en 2010
Impact of complete remission with intensive therapy in patients with responsive multiple myeloma
article by R Alexanian et al published May 2001 in Bone Marrow Transplantation
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
artículo científico publicado en 2011
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point
artículo científico publicado en 2015
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
artículo científico publicado en 2015
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study
scientific article published on 05 August 2016
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma
artículo científico publicado en 2015
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG).
artículo científico publicado en 2009
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents
artículo científico publicado en 2012
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
artículo científico publicado en 2018
Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece
artículo científico publicado en 2002
Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome
artículo científico publicado en 2012
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
artículo científico publicado en 2010
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment
artículo científico publicado en 2016
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents
scholarly article by Anna Tasidou et al published 6 May 2012 in American Journal of Hematology
Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma
Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma
artículo científico publicado en 2011
Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental
artículo científico publicado en 2009
Insights on Multiple Myeloma Treatment Strategies
artículo científico publicado en 2018
Intensive Sequential Therapy for VAD-Resistant Multiple Myeloma
artículo científico publicado en 1994
Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma.
artículo científico publicado en 1994
Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications
artículo científico publicado en 2011
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer
artículo científico publicado en 2011
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
artículo científico publicado en 2016
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
artículo científico publicado en 2011
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
artículo científico publicado en 2016
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
artículo científico publicado en 2014
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
artículo científico publicado en 2008
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
artículo científico publicado en 2009
International Myeloma Working Group recommendations for global myeloma care
artículo científico publicado en 2013
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease
artículo científico publicado en 2013
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
artículo científico publicado en 2020
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
artículo científico publicado en 2014
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
scientific article published on 25 June 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
artículo científico publicado en 2009
International prognostic scoring system for Waldenstrom macroglobulinemia
artículo científico publicado en 2009
International uniform response criteria for multiple myeloma.
artículo científico publicado en 2006
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
scientific article published on 09 November 2018
Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix
artículo científico publicado en 2006
Intravenous pamidronate for myeloma bone disease: can the dose be lowered?
artículo científico publicado en 2010
Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors
artículo científico publicado en 1990
Inverse Probability of Censoring Weighted Analysis to Adjust the Treatment Effect on Overall Survival for Subsequent Therapy: A Case Study in a Clinical Trial in Multiple Myeloma.
artículo científico publicado en 2014
Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel
artículo científico publicado en 2017
Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications
artículo científico publicado en 2020
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study
artículo científico publicado en 2005
Irreversibility of drug resistance in VAD-refractory myeloma
artículo científico publicado en 1992
Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?
scientific article published in January 2006
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
artículo científico publicado en 2019
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
artículo científico publicado en 2012
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies
scientific article published on 08 May 2019
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience
artículo científico publicado en 2015
Laparoscopy in the evaluation of women with unexplained ascites: an invaluable diagnostic tool
artículo científico publicado en 2007
Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone
artículo científico publicado en 1997
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
artículo científico publicado en 2010
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
artículo científico publicado en 2014
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
artículo científico publicado en 2009
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma
artículo científico publicado en 2008
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
artículo científico publicado en 2012
Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.
artículo científico publicado en 2014
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
artículo científico publicado en 2007
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
artículo científico publicado en 2008
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma
Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.
artículo científico
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias
artículo científico publicado en 2011
Lenalidomide: an update on evidence from clinical trials
artículo científico publicado en 2010
Less strength and more fractures for MGUS bones
article by E. Terpos et al published 30 January 2014 in Blood
Leukocytoclastic vasculitis after long-term treatment with sunitinib: a case report
artículo científico
Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome
article
Limited value of myeloablative therapy for late multiple myeloma.
artículo científico publicado en 1994
Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period
artículo científico publicado en 2020
Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy
artículo científico publicado en 2020
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
artículo científico publicado en 2009
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
artículo científico publicado en 2015
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group
artículo científico publicado en 1998
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: re
artículo científico publicado en 2018
Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature
scientific article published on February 2010
Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG)
article
Lymphoepithelioma-like carcinoma of the bladder
scientific article published on 01 January 2001
MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population
artículo científico publicado en 2013
MR imaging of complex tail-gut cysts.
artículo científico publicado en 1999
Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis.
artículo científico publicado en 2006
Magnetic resonance imaging of the bone marrow in hematologic malignancies
⬇️
artículo científico publicado el 15 de septiembre de 1997
Management of advanced bladder cancer in patients with impaired renal function
scientific article published on June 2011
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
scientific article published on 22 May 2020
Management of relapsed and relapsed refractory myeloma
artículo científico publicado en 2007
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
artículo científico publicado en 2011
Managing renal complications in multiple myeloma
artículo científico publicado en 2016
Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract
artículo científico publicado en 2008
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid
artículo científico publicado en 2010
Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies
scientific article published on 26 March 2019
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
artículo científico publicado en 2007
Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature
artículo científico publicado en 2013
Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
artículo científico publicado en 2017
Mitral valve prolapse in young healthy individuals. An early index of autoimmunity?
artículo científico publicado en 2009
Molecular aspects of multiple myeloma.
artículo científico publicado en 2000
Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.
artículo científico publicado en 2018
Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.
artículo científico publicado en 2011
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
artículo científico publicado en 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma
scientific article
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein
artículo científico publicado en 2004
Monoclonal gammopathy of undetermined significance: a consensus statement
artículo científico publicado en 2010
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy
artículo científico publicado en 2010
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
artículo científico publicado en 2007
Multifocal Extranodal Non-Hodgkin Lymphoma: A Clinicopathologic Study of 37 Cases in Greece, a Hellenic Cooperative Oncology Group Study
artículo científico publicado en 2005
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
Multiple Myeloma in the Era of Novel Agents
Multiple myeloma
article published in 2010
Multiple myeloma in elderly patients: prognostic factors and outcome
artículo científico publicado en 2005
Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era.
artículo científico publicado en 2012
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective
scientific article published on 26 March 2011
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
article
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
artículo científico publicado en 2013
Multiple myeloma: MR patterns of response to treatment.
artículo científico publicado en 1994
Multiple myeloma: Role of autologous transplantation
artículo científico publicado en 2019
Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease
artículo científico publicado el 1 de diciembre de 1992
Myeloablative therapy for primary resistant multiple myeloma.
artículo científico publicado en 1995
Myeloma bone disease and proteasome inhibition therapies.
artículo científico publicado en 2007
Myeloma bone disease: from biology findings to treatment approaches
artículo científico publicado en 2019
Myeloma bone disease: pathophysiology and management.
artículo científico publicado en 2005
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
artículo científico publicado en 2008
Myocardial adrenergic denervation in patients with primary (AL) amyloidosis
artículo científico publicado en 2003
Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma
artículo científico publicado en 2008
Neoadjuvant chemotherapy in invasive bladder cancer
artículo científico publicado en 2005
Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results
artículo científico publicado en 2004
Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma.
artículo científico publicado en 1994
Nephrotic syndrome as a manifestation of Toxocara canis infection
artículo científico publicado en 2006
Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma
artículo científico publicado en 2015
New Agents in Multiple Myeloma: An Examination of Safety Profiles
artículo científico publicado en 2017
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes
artículo científico publicado en 2012
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
artículo científico publicado en 2014
Next generation flow cytometry for MRD detection in patients with AL amyloidosis
artículo científico publicado en 2020
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years
scientific article published on 20 April 2011
Non-Hodgkin's lymphoma of the renal pelvis
artículo científico publicado en 2006
Non-Hodgkin’s Lymphomas in Greece according to the WHO Classification of Lymphoid Neoplasms
Non-secretory myeloma: one, two, or more entities?
artículo científico publicado en 2013
Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib
artículo científico publicado en 2008
Novel anti-myeloma agents and angiogenesis.
artículo científico publicado en 2008
Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents
artículo científico publicado en 2013
Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
artículo científico publicado en 2012
Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13,800 patients and 23,340 controls in 19 observational studies
artículo científico publicado en 2011
Once-weekly (70 mg/m2 ) vs twice-weekly (56 mg/m2 ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials
scientific article published on 28 February 2020
Optimal use of bisphosphonates in patients with multiple myeloma
artículo científico
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
scientific article published on 04 February 2011
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
artículo científico publicado en 2019
Oral estramustine and oral etoposide for hormone-refractory prostate cancer
⬇️
artículo científico publicado el 1 de noviembre de 1997
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors
artículo científico publicado en 2005
Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging
artículo científico publicado en 2015
Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis
artículo científico publicado en 2016
Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study.
artículo científico publicado en 2011
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit
artículo científico publicado en 2017
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin
artículo científico publicado en 2005
Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor
artículo científico publicado en 1999
Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice
artículo científico publicado en 2012
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
artículo científico publicado en 2016
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone
Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma
artículo científico publicado en 2016
Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study
artículo científico publicado en 2016
PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy
artículo científico publicado en 2015
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)
artículo científico publicado en 2000
Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study
Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.
artículo científico publicado en 1998
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2004
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2007
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG)
scientific article published on 29 September 2010
Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation
article
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial
artículo científico publicado en 2002
Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
artículo científico publicado en 2008
Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
artículo científico publicado en 2008
Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience
artículo científico publicado en 2008
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
artículo científico publicado en 2015
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
artículo científico publicado en 2014
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.
artículo científico publicado en 2017
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma
artículo científico
Pathogenesis and management of myeloma bone disease
scientific article published on August 2009
Pathogenesis and treatment of renal failure in multiple myeloma
artículo científico publicado en 2008
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
artículo científico publicado en 2018
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN)
Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
artículo científico publicado en 2004
Periodic Therapeutic Plasma Exchange in Patients With Moderate to Severe Chronic Myasthenia Gravis Non-Responsive to Immunosuppressive Agents: An Eight Year Follow-Up
artículo científico publicado en 2009
Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection
artículo científico publicado en 2020
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
artículo científico publicado en 2012
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
artículo científico publicado en 2011
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
artículo científico publicado en 2008
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma
artículo científico publicado en 2018
Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer
artículo científico publicado en 2005
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
artículo científico publicado en 2013
Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer
artículo científico publicado en 2003
Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma
artículo científico publicado en 2008
Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo
artículo científico publicado en 2009
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
artículo científico publicado en 2012
Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell trasplantation
artículo científico publicado en 2014
Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
artículo científico publicado en 2018
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
artículo científico publicado en 2015
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
artículo científico publicado en 2016
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
artículo científico publicado en 2013
Pomalidomide – An Appraisal of Its Clinical Development and Role in the Treatment of Relapsed/Refractory Multiple Myeloma
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
artículo científico publicado en 2020
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
scientific article published on 13 May 2019
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
artículo científico publicado en 2013
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma
artículo científico publicado en 2016
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
artículo científico publicado en 2017
Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2005
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
artículo científico publicado en 2007
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial
artículo científico publicado en 2011
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
artículo científico publicado en 2016
Prechemotherapy Serum Levels of CD105, Transforming Growth Factor β2, and Vascular Endothelial Growth Factor Are Associated With Prognosis in Patients With Advanced Epithelial Ovarian Cancer Treated With Cytoreductive Surgery and Platinum-Based Chem
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma
artículo científico publicado en 2013
Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis
artículo científico publicado en 1991
Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.
artículo científico publicado en 2005
Predictors of colorectal cancer screening awareness among people working in a hospital environment.
artículo científico publicado en 2017
Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure.
artículo científico publicado en 2006
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
artículo científico publicado en 2014
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases
artículo científico publicado en 2013
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network
artículo científico publicado en 2017
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.
artículo científico publicado en 2018
Prevention and treatment of myeloma bone disease
artículo científico
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
artículo científico publicado en 2007
Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy
article
Primary Systemic Amyloidosis (AL)
Primary Treatment of Waldenström Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide
artículo científico publicado en 2007
Primary dexamethasone treatment of multiple myeloma
⬇️
artículo científico publicado el 15 de agosto de 1992
Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance
artículo científico publicado en 2016
Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG).
artículo científico publicado en 2006
Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy
artículo científico publicado en 1995
Primary mediastinal large B-cell lymphoma: clinical study of a distinct clinical entity and treatment outcome in 20 patients: review of the literature
artículo científico publicado en 2004
Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy
artículo científico publicado en 1997
Primary parotid lymphoma: the effect of international prognostic index on outcome
⬇️
artículo científico publicado el 1 de junio de 1997
Primary plasma cell leukaemia
artículo científico publicado en 1994
Primary plasma cell leukemia presenting as secondary pulmonary alveolar proteinosis
scientific article published on 13 May 2020
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
artículo científico publicado en 2013
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
artículo científico publicado en 2019
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2002
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
artículo científico publicado en 2004
Primary treatment with 2-chiorodeoxyadenosine of low grade lymphomas that produce igg or IgA immunoglobulin
scientific article published on 01 August 1993
Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma
artículo científico publicado en 2006
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
artículo científico publicado en 2014
Prognosis and risk assessment in AL amyloidosis - There and back again
artículo científico publicado en 2017
Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience
Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
artículo científico publicado en 2017
Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.
artículo científico publicado en 2011
Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience
artículo científico publicado en 2011
Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma
artículo científico publicado en 2003
Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG)
artículo científico publicado en 2013
Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study
artículo científico publicado en 2014
Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma
artículo científico publicado en 2005
Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model
artículo científico publicado en 2010
Prognostic value of cytogenetics in multiple myeloma
scientific article published on 01 April 1998
Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA).
artículo científico publicado en 2008
Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment.
artículo científico publicado en 2006
Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase
artículo científico publicado en 2009
Prognostication of the High-Risk WM Patient
artículo científico publicado en 2011
Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis
artículo científico publicado en 2013
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial
artículo científico publicado en 2010
Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation
Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.
artículo científico publicado en 2003
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
artículo científico publicado en 2012
Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease
artículo científico publicado en 2009
Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging
artículo científico publicado en 2013
Proteasome inhibitor associated thrombotic microangiopathy
artículo científico publicado en 2016
Proteasome inhibitor therapy for Waldenström's macroglobulinemia
artículo científico publicado en 2013
Prunart Renal Lymphoma
Prunart Renal Lymphoma: A Clinical and Radiological Study
artículo científico publicado en 1996
Pseudohyperphosphatemia in multiple myeloma
artículo científico publicado en 1996
Pulmonary toxicity from novel antineoplastic agents
artículo científico publicado en 2005
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments
artículo científico publicado en 2007
Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma
artículo científico publicado en 2004
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
artículo científico publicado en 2019
Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma
artículo científico publicado en 2016
Quiz Case: A 19-Year-Old Woman with Hypercalcemia and Abdominal Pain
scientific article published on 21 February 2012
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
artículo científico publicado en 2009
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
artículo científico publicado en 2009
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents.
artículo científico publicado en 2012
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group
artículo científico publicado en 2020
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
scientific article published on 01 April 2020
Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd
scientific article published on 09 March 2020
Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma
artículo científico publicado en 2016
Recent advances in the management of AL Amyloidosis
artículo científico publicado en 2015
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
artículo científico publicado en 2016
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
artículo científico publicado en 2008
Relapse of Ovarian Cancer With Bone Marrow Infiltration and Concurrent Emergence of Therapy-Related Acute Myeloid Leukemia: A Case Report
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
artículo científico publicado en 2016
Renal failure in multiple myeloma: incidence, correlations, and prognostic significance
artículo científico publicado en 2007
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group
artículo científico publicado en 2010
Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens
artículo científico publicado en 2011
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
artículo científico publicado en 2017
Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause
artículo científico publicado en 2020
Replication protein A in nonearly ovarian adenocarcinomas: correlation with MCM-2, MCM-5, Ki-67 index and prognostic significance
artículo científico publicado en 2012
Reply to C.A. Hutchison et al
Reply to D.L. Cooper
Reply to S. Girnius et al.
artículo científico publicado en 2013
Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): A risk adapted protocol of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2009
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP
artículo científico publicado en 2018
Response to bortezomib of a patient with scleromyxedema refractory to other therapies
article
Response to letter, 'immortal time bias in retrospective analysis'.
artículo científico publicado en 2015
Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma
artículo científico publicado en 2014
Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy
artículo científico publicado en 2003
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
artículo científico publicado en 2007
Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents
artículo científico publicado en 2010
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors
artículo científico publicado en 2009
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
artículo científico publicado en 2015
Rhodotorula septicemia: case report and minireview
artículo científico publicado en 2001
Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma.
artículo científico publicado en 1995
Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses
artículo científico publicado en 2015
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.
artículo científico publicado en 2010
Risk of disease progression in asymptomatic multiple myeloma
artículo científico publicado en 1993
Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma
artículo científico publicado en 2003
Rituximab therapy in monoclonal IgM-related neuropathies
artículo científico publicado en 2006
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care
artículo científico publicado en 2012
Rituximab-based treatments in Waldenström's macroglobulinemia
scientific article published on March 2009
Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder
artículo científico publicado en 1998
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement
artículo científico publicado en 2015
Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)
scientific article published on 01 September 2004
Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.
artículo científico publicado en 2015
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
artículo científico publicado en 2016
Sarcomas of the fallopian tube: disentangling a rare entity.
artículo científico publicado en 2011
Sclerostin: a possible target for the management of cancer-induced bone disease
artículo científico
Screening for Gaucher disease among patients with plasma cell dyscrasias
artículo científico publicado en 2019
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
artículo científico publicado en 2014
Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma.
artículo científico publicado en 2018
Sequential Administration of Doxorubicin and Paclitaxel Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil Combination (CMF) in Women with Metastatic Breast Cancer
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study
artículo científico publicado en 2011
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report
scientific article published on 21 September 2020
Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?
artículo científico publicado en 2012
Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
artículo científico publicado en 2006
Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity
article
Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome.
artículo científico publicado en 2016
Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.
artículo científico publicado en 2014
Significant reduction in the visits to the emergency room department during the COVID-19 pandemic in a tertiary hospital in Greece: Indirect victims of the pandemic?
artículo científico publicado en 2020
Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations
artículo científico publicado en 2009
Solitary bone plasmacytoma and extramedullary plasmacytoma
artículo científico publicado en 2002
Solitary bone plasmacytomas need to flow
artículo científico publicado en 2014
Solitary plasmacytoma of bone and asymptomatic multiple myeloma
artículo científico publicado en 2000
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
artículo científico publicado en 1992
Solitary plasmacytoma of bone and extramedullary plasmacytoma
artículo científico publicado en 1999
Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication
artículo científico publicado en 2009
Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature review
artículo científico publicado en 2017
Staging and prognostication of multiple myeloma
artículo científico
Stauffer's syndrome as a prominent manifestation of renal cancer: a case report
artículo científico publicado en 2009
Study of T Lymphocytes Infiltrating Peritoneal Metastases in Advanced Ovarian Cancer
scientific article published on 01 November 2009
Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer
artículo científico publicado en 2005
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases
artículo científico publicado en 2000
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
artículo científico publicado en 2000
Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.
artículo científico publicado en 2009
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
artículo científico publicado en 2010
Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia
artículo científico publicado en 2003
Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone
artículo científico publicado en 2009
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival.
artículo científico publicado en 2006
Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer
Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes
artículo científico publicado en 2020
Systemic chemotherapy in inoperable or metastatic bladder cancer
artículo científico publicado en 2005
TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma
artículo científico publicado en 2015
Tanespimycin as antitumor therapy.
artículo científico publicado en 2011
Targeted therapies in multiple myeloma
artículo científico publicado en 2009
Thalidomide and dexamethasone combination for refractory multiple myeloma
artículo científico publicado en 2001
Thalidomide and immunomodulatory drugs in the treatment of cancer
artículo científico publicado en 2005
Thalidomide for myeloma: still here?
scientific article published on 01 October 2018
Thalidomide in cancer medicine
artículo científico publicado en 2004
Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States
artículo científico publicado en 2003
Thalidomide in the treatment of multiple myeloma
artículo científico publicado en 2007
Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma
artículo científico publicado en 2008
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
artículo científico publicado en 2016
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EP
artículo científico publicado en 2013
The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
artículo científico publicado en 2016
The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens
artículo científico publicado en 2008
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function
article by Athanasios Dimopoulos et al published 7 June 2011 in Annals of Oncology
The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016.
artículo científico publicado en 2016
The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma
scientific article published on 25 September 2020
The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents
artículo científico publicado en 2017
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
artículo científico publicado en 2008
The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2003
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group
artículo científico publicado en 2005
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2006
The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio
artículo científico publicado en 2005
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group
scholarly article by Evangelos Terpos et al published 15 October 2013 in American Journal of Hematology
The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia
scientific article published on 13 July 2020
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
artículo científico publicado en 2007
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison
scientific article published on 05 November 2019
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
artículo científico publicado en 2010
The evolving role of lenalidomide in the treatment of hematologic malignancies
artículo científico publicado en 2007
The expanding role of fludarabine in hematologic malignancies
artículo científico publicado en 1994
The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy
artículo científico publicado en 2006
The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
artículo científico publicado en 2004
The mediterranean diet in cancer prevention: a review
artículo científico publicado en 2011
The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy
artículo científico publicado en 2005
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy
artículo científico publicado en 2005
The patient with myeloma
The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates
artículo científico publicado en 1998
The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma
artículo científico publicado en 2014
The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect
artículo científico publicado en 2011
The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma
artículo científico publicado en 2014
The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)
scholarly article by Charalampia Kyriakou et al published 26 February 2019 in Blood Cancer Journal
The role of high-dose chemotherapy in the treatment of testicular cancer.
artículo científico
The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma
artículo científico
The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma
The role of novel drugs in multiple myeloma
artículo científico publicado en 2008
The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer
artículo científico publicado en 2011
The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies
artículo científico publicado en 2015
The treatment of multiple myeloma
artículo científico publicado en 1994
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
scientific article published on 02 September 2010
The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view.
artículo científico publicado en 1995
Therapeutic plasma exchange combined with immunomodulating agents in secondary progressive multiple sclerosis patients.
artículo científico publicado en 2008
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents
article
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicity
article
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
artículo científico publicado en 2001
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer
artículo científico publicado en 2010
Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association?
artículo científico publicado en 2011
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis
artículo científico publicado en 2020
Tobacco smoking and risk of multiple myeloma: A meta-analysis of 40 observational studies
article
Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop
artículo científico publicado en 2019
Treatment Recommendations in Waldenström Macroglobulinemia
Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation
artículo científico publicado en 2006
Treatment of Waldenstrom's Macroglobulinemia
artículo científico publicado en 2007
Treatment of Waldenstrom's Macroglobulinemia with Nucleoside Analogues
artículo científico publicado en 1993
Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression
article
Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors
artículo científico publicado en 1995
Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone
artículo científico publicado en 2003
Treatment of Waldenstrom's macroglobulinemia with thalidomide
artículo científico publicado en 2001
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide
artículo científico publicado en 2003
Treatment of Waldenström's macroglobulinemia with rituximab
artículo científico publicado en 2002
Treatment of early uterine sarcomas: disentangling adjuvant modalities
artículo científico publicado en 2009
Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study
artículo científico publicado en 2003
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
artículo científico publicado en 2002
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
artículo científico publicado en 2007
Treatment of light chain deposition disease with bortezomib and dexamethasone
artículo científico publicado en 2009
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program
artículo científico publicado en 2005
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study
artículo científico publicado en 2004
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
artículo científico publicado en 2003
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel
artículo científico publicado en 1998
Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens
artículo científico publicado en 2008
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies
artículo científico publicado en 2010
Treatment of plasma cell dyscrasias with lenalidomide
artículo científico publicado en 2008
Treatment of plasma cell dyscrasias with thalidomide and its derivatives
artículo científico publicado en 2003
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
artículo científico publicado en 2010
Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
artículo científico publicado en 2005
Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group
artículo científico publicado en 2015
Treatment of relapsed/refractory multiple myeloma
artículo científico publicado en 2009
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors
artículo científico publicado en 2004
Treatment options for relapsed and refractory multiple myeloma
artículo científico
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus
artículo científico publicado en 2014
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
artículo científico publicado en 2016
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
artículo científico publicado en 2013
Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function
article
Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
artículo científico
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues
artículo científico publicado en 2010
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer.
artículo científico publicado en 2002
Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).
artículo científico publicado en 2015
Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group
artículo científico publicado en 2007
Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center.
artículo científico publicado en 2016
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
artículo científico publicado en 2006
Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma
artículo científico publicado en 2009
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia
artículo científico publicado en 2008
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
artículo científico publicado en 2006
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial
artículo científico publicado en 2016
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
artículo científico publicado en 2017
Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).
artículo científico publicado en 2015
VAD-Cyclosporine Therapy for VAD-Resistant Multiple Myeloma
scientific article published in January 1995
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group
artículo científico publicado en 2007
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
artículo científico publicado en 2016
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
artículo científico publicado en 2012
VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
article by Apostolos C. Ziogas et al published 25 May 2011 in International Journal of Cancer
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s
artículo científico publicado en 2009
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
artículo científico publicado en 2013
VWF, WM, and angiogenesis: is there a link?
Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)
artículo científico publicado en 2010
Venous thromboembolic events alert for gynecologic neoplasms.
artículo científico publicado en 2010
Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials
artículo científico publicado en 2002
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
artículo científico publicado en 2014
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma.
artículo científico publicado en 2014
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
artículo científico publicado en 2013
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
artículo científico publicado en 2013
Waldenström macroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features
artículo científico publicado en 1995
Waldenström macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis.
artículo científico publicado en 1993
Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Waldenström's macroglobulinemia
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics
artículo científico publicado en 2016
Waldenström's macroglobulinemia: clinical features, complications, and management
artículo científico publicado en 2000
Waldenström’s Macroglobulinemia
Waldenström’s Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group
artículo científico publicado en 2009
Wegener's granulomatosis presenting as a renal mass
artículo científico publicado en 2008
When a little aspirin may be enough
When to recommend a second autograft in patients with relapsed myeloma?
artículo científico publicado en 2016
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group.
artículo científico publicado en 2017
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience
artículo científico publicado en 2006
Zoledronic acid for all patients with newly diagnosed multiple myeloma?
artículo científico publicado en 2011